Isryl-M 1 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glucose utilization. The combined formulation offers complementary mechanisms of action, providing effective glycemic regulation in patients inadequately controlled by diet, exercise, or monotherapy. Isryl-M 1 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. The extended-release formulation ensures sustained plasma drug levels, promoting better compliance and minimizing gastrointestinal side effects commonly associated with Metformin. Caution is advised in patients with renal or hepatic impairment, heart failure, or conditions predisposing to hypoxia, as these may increase the risk of lactic acidosis or hypoglycemia. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Isryl-M 1 Tablet PR should be used under medical supervision, with dose adjustments based on therapeutic response and tolerability.